Masks for a rare pathology: A clinical case of lysosomal acid lipase deficiency with asymptomatic onset and delayed verification of diagnosis

Lysosomal acid lipase deficiency (LALD, cholesterol ester storage disease, OMIM #278000) is a rare autosomal recessive disorder resulting from underlying LIPA gene mutations, leading to impaired hydrolysis of cholesterol esters and triglycerides within lysosomes. Common presenting symptoms include hepatomegaly, dyslipidemia, increased transaminases, steatosis, and in severe forms – progressive liver fibrosis and early atherosclerosis. The presented clinical case describes the management of LALD in an 8-year-old girl, characterized by early age onset, absence of typical delay in physical development and pronounced polymorphism of clinical manifestations. For several years, gastrointestinal symptoms combined with anemia, nosebleeding, and fatigue, which were evaluated as functional disorders prevailed. The diagnostic search was initiated late, despite the presence of hepatomegaly, persistent hypercholesterolemia, and elevated transaminases. The diagnosis was verified based on decreased enzymatic activity of lysosomal acid lipase and results of the molecular genetic analysis (variant c.894G>A in the LIPA gene in the homozygous state). Liver steatosis and fibrosis progression was observed in the absence of timely initiation of enzyme replacement therapy. A clinical example demonstrates the difficulties of early diagnosis of lysosomal storage diseases in pediatric practice. The case highlights the diagnostic challenges due to phenotypic variability and clinical similarities with more common disorders, including familial hypercholesterolemia. The article discusses differential diagnostic approaches, including exclusion of viral hepatitis, Wilson's disease, autoimmune liver diseases, and hereditary metabolic diseases. The need for early diagnosis, family screening and optimization of access to enzyme replacement therapy has been underlined. The article also outlines promising directions in the development of neonatal screening programs and areas of targeted therapy, including gene technologies. This case emphasizes the need to increase the alertness of clinicians and introduce systemic diagnostic algorithms into clinical practice.

1. Burton BK, Deegan PB, Enns GM, Guardamagna O, Horslen S, Hovingh GK et al. Clinical features of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr. 2015;61(6):619–625. https://doi.org/10.1097/mpg.0000000000000935.

2. Bernstein DL, Lobritto S, Luga A, Remotti H, Schiano T, Fiel MI, Balwani M. Lysosomal acid lipase deficiency allograft recurrence and liver failure-clinical outcomes of 18 liver transplantation patients. Mol Genet Metab. 2018;124(1):11–19. https://doi.org/10.1016/j.ymgme.2018.03.010.

3. Besler KJ, Blanchard V, Francis GA. Lysosomal acid lipase deficiency: a rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease. Front Genet. 2022;13:1013266. https://doi.org/10.3389/fgene.2022.1013266.

4. Korbelius M, Kuentzel KB, Bradic I, Vujic N, Kratky D. Recent insights into lysosomal acid lipase deficiency. Trends Mol Med. 2023;29(6):425–438. https://doi.org/10.1016/j.molmed.2023.03.001.

5. Reiner Ž, Guardamagna O, Nair D, Soran H, Hovingh K, Bertolini S et al. Lysosomal acid lipase deficiency–an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235(1):21–30. https://doi.org/10.1016/j.atherosclerosis.2014.04.003.

6. Sheth S, Toth PP, Baum SJ, Aggarwal M. Distinguishing lysosomal acid lipase deficiency from familial hypercholesterolemia. JACC Case Rep. 2023;24:102023. https://doi.org/10.1016/j.jaccas.2023.102023.

7. Balwani M, Balistreri W, DAntiga L, Evans J, Ros E, Abel F, Wilson DP. Lysosomal acid lipase deficiency manifestations in children and adults: Baseline data from an international registry. Liver Int. 2023;43(7):1537–1547. https://doi.org/10.1111/liv.15620.

8. Witeck CR, Schmitz AC, de Oliveira JMD, Porporatti AL, Canto GDL, de Souza Pires MM. Lysosomal acid lipase deficiency in pediatric patients: a scoping review. J de Pediatria. 2022;98(1):4–14. https://doi.org/10.1016/j.jped.2021.03.003.

9. Himes RW, Barlow SE, Bove K, Quintanilla NM, Sheridan R, Kohli R. Lysosomal acid lipase deficiency unmasked in two children with nonalcoholic fatty liver disease. Pediatrics. 2016;138(4):e20160214. https://doi.org/10.1542/peds.2016-0214.

10. Gómez-Nájera M, Barajas-Medina H, Gallegos-Rivas MC, Mendez-Sashida P, Goss KA, Sims KB et al. New diagnostic method for lysosomal acid lipase deficiency and the need to recognize its manifestation in infants (Wolman disease). J Pediatr Gastroenterol Nutr. 2015;60(3):e22-e24. https://doi.org/10.1097/mpg.0000000000000175.

11. Mashima R, Takada S. Lysosomal acid lipase deficiency: Genetics, screening, and preclinical study. Int J Mol Sci. 2022;23(24):15549. https://doi.org/10.3390/ijms232415549.

12. Burton BK, Sanchez AC, Kostyleva M, Martins AM, Marulkar S, Abel F, Baric I. Long-term sebelipase alfa treatment in children and adults with lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr. 2022;74(6):757–764. https://doi.org/10.1097/mpg.0000000000003452.

13. Burton BK, Feillet F, Furuya KN, Marulkar S, Balwani M. Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study. J Hepatol. 2022;76(3):577–587. https://doi.org/10.1016/j.jhep.2021.10.026.

14. de Castro MJ, Jones SA, de Las Heras J, Sanches-Pintos P, Couce ML, Colon C et al. Twice weekly dosing with Sebelipase alfa (Kanuma®) rescues severely ill infants with Wolman disease. Orphanet J Rare Dis. 2024;19(1):244. https://doi.org/10.1186/s13023-024-03219-5.

15. de Las Heras J, Almohalla C, Blasco-Alonso J, Bourbon M, Couce ML, de Castro Lopez MJ et al. Practical Recommendations for the Diagnosis and Management of Lysosomal Acid Lipase Deficiency with a Focus on Wolman Disease. Nutrients. 2024;16(24):4309. https://doi.org/10.3390/nu16244309.

16. Nedelcu C, Dijmarescu I, Patrascoiu M, Oprescu I, Pacurar D. Lysosomal Acid Lipase Deficiency: A Report of Two Cases and a Review of the Literature. Cureus. 2024;16(11):e73299. https://doi.org/10.7759/cureus.73299.

17. Anisimova IV, Albegova MB, Bagaeva ME, Baidakova GV, Baranov AA, Vashakmadze ND et al. Clinical guidelines for the management of children with lysosomal acid lipase deficiency. Pediatric Pharmacology. 2023;20(4):337–354. (In Russ.) https://doi.org/10.15690/pf.v20i4.2602.

18. Greshnyakova VA, Goryacheva LG, Makarevskaya NYu. Lysosomal acid lipase deficiency in the practice of an infectious disease doctor: clinical cases. RMJ. 2022;(5):40–45. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Deficit_lizosomnoy_kisloy_lipazy_v_praktike_vracha-infekcionista_klinicheskie_nablyudeniya/.

19. Laurent M, Harb R, Jenny C, Oustelandt J, Jimenez S, Cosette J et al. Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer. Commun Med. 2025;5(1):110. https://doi.org/10.1038/s43856-025-00816-8.

20. Lam P, Zygmunt DA, Ashbrook A, Yan C, Du H, Martin PT. Liver-directed aav gene therapy normalizes disease symptoms and provides cross-correction in a model of lysosomal acid lipase deficiency. Mol Ther. 2024;32(12):4272–4284. https://doi.org/10.1016/j.ymthe.2024.10.022.